Skip to main content
S&P 5007,803.03-0.20%DOW51,234.59-0.56%NASDAQ27,498.81-0.37%BTC$83,247.00-2.73%ETH$2,560.04-5.02%GOLD$4,145.40-1.00%OIL$88.36-1.21%
Smart Investors Daily
SID Premium
XE

NASDAQ · XENE

Xenon Pharmaceuticals Inc.

Healthcare · Biotechnology

$36.57

Down-$0.25 (-0.69%)

Updated Oct 7, 2026, 5:29 PM

SID Score

3.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.37B
P/E ratio
-12.39
Dividend yield
0.00%
52-week range
$35.75 – $72.66
Volume
2.79M
Avg. volume
790.48K

Price performance · XENE

XENE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

XENE closed at $36.57 after 21 trading sessions, down 38.59% for the selected period.

Last close
$36.57
Period change
-38.59%
Period low
$36.56
Period high
$59.55
Daily close
View OHLC price history
XENE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$37.78$37.79$35.75$36.572.79M
Oct 5, 2026$38.02$38.225$37.00$37.571.7M
Oct 2, 2026$39.10$39.10$37.26$38.021.94M
Oct 1, 2026$38.31$39.92$38.08$38.933.66M
Sep 30, 2026$37.38$37.5325$36.71$37.192.47M
Sep 29, 2026$36.30$37.43$36.20$37.252.75M
Sep 28, 2026$36.85$36.85$36.1014$36.722.52M
Sep 25, 2026$38.10$38.26$36.48$36.942.43M
Sep 24, 2026$36.50$38.34$36.07$38.063.11M
Sep 23, 2026$39.51$39.51$36.07$36.563.17M
Sep 22, 2026$39.76$39.76$37.97$39.092.35M
Sep 21, 2026$40.00$40.26$38.6045$38.994.05M
Sep 18, 2026$44.02$44.85$39.08$39.7517.95M
Sep 17, 2026$57.60$58.15$56.87$57.351.83M
Sep 16, 2026$56.67$57.875$56.40$56.76723.67K
Sep 15, 2026$58.13$58.13$56.17$56.28587.02K
Sep 14, 2026$59.36$59.60$58.00$58.19408.95K
Sep 11, 2026$60.00$60.00$58.53$58.65466.75K
Sep 10, 2026$58.74$59.395$58.00$58.80798.78K
Sep 9, 2026$59.04$59.81$58.53$58.98489.45K
Sep 8, 2026$58.95$60.36$58.27$59.55608.51K

Latest XENE news

The latest Smart Investors Daily articles mentioning XENE.

Stock researchCompany · Overview

XENE research

Overview

Company profile and research snapshot.

Company profile

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$52.33
Implied upside
—
Analysts
—
XENE recent ratings
DateFirmRatingTarget
Sep 18, 2026WedbushOutperform—
Sep 18, 2026RBC CapitalOutperform—
Sep 18, 2026Wells FargoOverweight—
Sep 18, 2026Deutsche BankHold—
Sep 18, 2026BairdOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were a

Yahoo · Sep 29, 2026

Ian Mortimer Receives the 2026 Bloom Burton Award

Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award. 2026 Bloom Burton Award Winner Ian Mortimer, President and Chief Executive Officer of Xenon PharmaceuticalsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/6420/316465_7cc4242184cef922_001full.jpgIn the past..

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By